Balance Sheet
Cash Flow Statement
Capital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in IntangiblesChange in InventoryChange in ReceivablesChange in TaxesDeferred TaxesDepreciation & Amortization (CF)Exchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesOther financing activitiesSales of Property, Plant and EquipmentShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Gyre Therapeutics (GYRE) Depreciation & Amortization (CF) (2016 - 2025)

Gyre Therapeutics (GYRE) has disclosed Depreciation & Amortization (CF) for 16 consecutive years, with $649000.0 as the latest value for Q3 2025.

  • On a quarterly basis, Depreciation & Amortization (CF) rose 45.84% to $649000.0 in Q3 2025 year-over-year; TTM through Sep 2025 was $1.8 million, a 31.67% increase, with the full-year FY2023 number at $1.1 million, down 1.2% from a year prior.
  • Depreciation & Amortization (CF) was $649000.0 for Q3 2025 at Gyre Therapeutics, up from $641000.0 in the prior quarter.
  • In the past five years, Depreciation & Amortization (CF) ranged from a high of $867000.0 in Q4 2022 to a low of $40000.0 in Q3 2022.
  • A 5-year average of $298000.0 and a median of $252000.0 in 2023 define the central range for Depreciation & Amortization (CF).
  • Peak YoY movement for Depreciation & Amortization (CF): soared 653.91% in 2022, then crashed 65.63% in 2023.
  • Gyre Therapeutics' Depreciation & Amortization (CF) stood at $115000.0 in 2021, then skyrocketed by 653.91% to $867000.0 in 2022, then plummeted by 65.63% to $298000.0 in 2023, then skyrocketed by 49.33% to $445000.0 in 2024, then surged by 45.84% to $649000.0 in 2025.
  • Per Business Quant, the three most recent readings for GYRE's Depreciation & Amortization (CF) are $649000.0 (Q3 2025), $641000.0 (Q2 2025), and $535000.0 (Q1 2025).